General Information of This Drug (ID: DMAG6BV)

Drug Name
LGK974   DMAG6BV
Synonyms
1243244-14-5; LGK974; LGK-974; 2-(2',3-Dimethyl-[2,4'-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide; WNT-974; LGK 974; UNII-U27F40013Q; CHEBI:78030; CHEMBL3188386; U27F40013Q; AK165831; 2-(2',3-dimethyl-2,4'-bipyridin-5-yl)-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide; MLS006011002; SCHEMBL1723611; KS-00000SUI; MolPort-029-945-290; HMS3653G11; BCP08495; EX-A1402; ZINC95930187; STL556617; BDBM50133870; BBL102809; 2140AH; s7143; AKOS025211913; SB19314; CS-2807; DB12561; NCGC00347950-07; NCGC00347950-01; OR302651; QC-11701
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
LGK974 + Marizomib DCLZOEK Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
LGK974 + Idarubicin DCONK4Q Idarubicin Glioblastoma? (Cell Line: T98G) [2]
LGK974 + Ruxolitinib DCFGM5S Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [3]
------------------------------------------------------------------------------------
1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
LGK974 + LGX818 DCK529K LGX818 Metastatic Colorectal Cancer [4]
------------------------------------------------------------------------------------

References

1 Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9.
2 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
3 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
4 ClinicalTrials.gov (NCT02278133) Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations